Aeras Global TB Vaccine Foundation and the China National Biotech Group (CNBG) announced the signing of a memorandum of understanding for the organizations to pursue opportunities to jointly develop tuberculosis (TB) vaccines in China and potentially other parts of the world. The partnership is intended to leverage both organizations' capabilities to support the development of TB vaccines. TB is a major public health priority in China, where there are more than one million new TB cases every year. The scope of potential activities will cover the full spectrum of product development, including pre-clinical development, process development and manufacturing, and clinical development in TB and potentially other disease areas. Details of the specific activities and areas of focus of the collaboration will be set forth in a future definitive agreement.